Welcome to our dedicated page for Vyne Therapeutics news (Ticker: VYNE), a resource for investors and traders seeking the latest updates and insights on Vyne Therapeutics stock.
Vyne Therapeutics Inc. (VYNE) is a clinical-stage biopharmaceutical company pioneering novel therapies for immuno-inflammatory conditions and dermatologic disorders. This dedicated news hub provides investors and industry professionals with timely updates on Vyne's clinical trials, regulatory milestones, and scientific advancements.
Access authoritative information on Vyne's BET inhibitor pipeline, including BD2-selective candidates like VYN201 (topical) and VYN202 (oral), designed to address chronic inflammatory diseases with improved safety profiles. Our curated news collection covers essential developments across preclinical research, FDA communications, and strategic partnerships.
Key updates include progress in treating conditions such as prurigo nodularis, vitiligo, and atopic dermatitis through Vyne's proprietary InhiBET platform. Bookmark this page for real-time notifications on Phase 2 trial results, intellectual property developments, and analyses of Vyne's position within the dermatology therapeutics market.
VYNE Therapeutics has announced promising preclinical data on its novel pan-BET inhibitor, VYN201, for treating idiopathic pulmonary fibrosis (IPF). VYN201 demonstrated significant reductions in lung fibrosis and hydroxyproline levels compared to placebo. Specifically, at doses of 0.5 mg/ml and 1 mg/ml, VYN201 achieved a 65.8% reduction in lung fibrosis scores and an 8.8% improvement in blood oxygen saturation. The treatment also led to a 51.8% increase in functional lung volume. These results support the potential broad utility of VYN201 as a locally-administered anti-inflammatory and anti-fibrotic therapy. VYNE is currently evaluating VYN201 in a Phase 1b study for non-segmental vitiligo, seeking to further validate its safety and efficacy.
VYNE Therapeutics announced positive results from the Phase 1a trial of its investigational BET inhibitor, VYN201, designed for topical administration. Key findings reveal no quantifiable plasma concentrations of VYN201, which supports its 'soft' drug approach. Furthermore, all hematological parameters, including platelet counts, remained within normal ranges, a significant improvement compared to systemically administered BET inhibitors. The trial enrolled 30 healthy volunteers and demonstrated no serious adverse events. The Phase 1b results, focusing on patients with nonsegmental vitiligo, are expected in mid-2023, potentially marking a new treatment avenue in this therapeutic area.
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced participation in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference on March 30, 2023. CEO David Domzalski and Chief Scientific Officer Dr. Iain Stuart will engage in a fireside chat at 3:30 PM ET. Investors can also schedule 1-on-1 meetings during the event. The discussion will cover the company’s innovative therapies for immuno-inflammatory conditions, including their lead programs, VYN201 and VYN202. A replay of the webcast will be available on the company's website for 90 days post-conference. For details, visit vynetherapeutics.com.
FAQ
What is the current stock price of Vyne Therapeutics (VYNE)?
What is the market cap of Vyne Therapeutics (VYNE)?
